Kancera reports dosing of first patient in the KANDOVA study
Kancera AB (publ) today reports that the first patient in the KANDOVA study, a combined phase Ib/IIa study in ovarian cancer, has been dosed with KAND567.
“The KANDOVA study is our first clinical study in cancer and having dosed the first patient is a very important milestone for Kancera”, says Thomas Olin, CEO at Kancera.
As previously has been announced, the KANDOVA-study is a combined phase Ib/IIa study of the Fractalkine-blocking drug candidate KAND567 in ovarian cancer patients with relapse from carboplatin. The study is conducted in collaboration with the clinical trials unit of the Nordic Society of Gynaecological Oncology (NSGO-CTU) and is planned to be conducted at several leading University hospitals in Sweden, Denmark and Norway. As of today, two sites have been initiated and have started patient screening and two additional sites are expected to be initiated in August. The objective is to recruit 30 patients in total for the combined phase Ib/II study and to present top line results during H2 2024.
Ovarian cancer is one of the most lethal cancer diseases as patients are often diagnosed at a very late stage resulting in a poor long term survival prognosis. Today’s standard of care treatment is based on platinum chemotherapy, e.g. carboplatin, aimed to cause DNA damage to the cancer cells. However, this treatment has limitations as the cancer cells develop treatment resistance by repairing the DNA damage caused by chemotherapy. In the KANDOVA-study, Kancera is studying treatment with KAND567 in ovarian cancer patients with relapse from carboplatin. The primary objective is to evaluate safety and tolerability of KAND567 treatment in combination with carboplatin. The secondary objective is to evaluate evidence of KAND567’s treatment efficacy. The long-term objective is to restore sensitivity to platinum treatment and thereby inhibit tumor growth and prolong survival.
About Kancera AB (publ)
Kancera is developing a new class of drugs for treatment of cancer and severe inflammatory diseases. Kancera’s main focus is to develop small molecule drug candidates based on the Fractalkine system. Fractalkine is a natural master regulator that with precision controls immune cells and cancer cells. Kancera’s most advanced fractalkine blocking drug candidate KAND567 is currently studied in two clinical studies, FRACTAL, a phase IIa study in myocardial infarction and KANDOVA, a combined phase Ib/IIa study in ovarian cancer. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser.
For further information:
Thomas Olin
Chief Executive Officer, Kancera AB
Tel: +46-73-620 40 01
Visit Kancera’s web page: https://www.kancera.com/en